DIA's members come together to collaborate and problem-solve, discussing global and local challenges facing the life sciences field in an increasingly more complex and interconnected world. DIA's goal, and our members' hope, is for this collaboration to result in better policies, regulations, science, research and development, and ultimately better patient outcomes worldwide.
DIA Mission
DIA fosters innovation to improve health and well-being worldwide by:
- Providing invaluable forums to exchange vital information and discuss current issues related to healthcare products, technologies, and services;
- Delivering customized learning experiences;
- Building, maintaining, and facilitating trusted relationships with and among individuals and organizations that drive and share DIA values and mandates; and
- Offering a multidisciplinary neutral environment, respected globally for integrity and relevancy.
DIA Vision
Our Annual Updates
Our Leadership
-
Joseph Scheeren,
PharmD •Chair DIA
Senior Advisor R&D
Bayer AG -
John A. Roberts,
MBA •Immediate Past Chair DIA
President and Chief Executive Officer
Cancer Genetics, Inc. (CGI) -
Rebecca Vermeulen,
RPh •Chair-Elect DIA
Head, Product Development Medical Affairs Customer Strategy
F. Hoffmann-La Roche Ltd. -
Jeffrey S. Payne,
CPA, CGMA •Secretary/Treasurer DIA
Chief Financial Officer
Katabat -
Barbara Lopez Kunz,
MS • Global Chief Executive
DIA
-
Andrzej Czarnecki,
MD, PhD, DSc •Director DIA
Director, Deputy Qualified Person for Pharmacovigilance, Global Patient Safety
Eli Lilly and Company, Ltd. -
Angelika Joos,
MPharm •Director DIA
Executive Director, Global Regulatory Policy
Merck Sharp & Dohme (Europe) Inc. -
Judith Ng-Cashin,
MD •Director DIA
Chief Scientific Officer
Syneos Health -
Michael Romano,
CPA •Director DIA
Partner, Life Science Industry Practice Group, RSM US -
Michael Rosenblatt,
MD •Director DIA
Chief Medical Officer
Flagship Pioneering -
Jonathan Sheldon,
PhD •Director DIA
Senior Vice President
QIAGEN -
Kihito Takahashi,
MD, PhD •Director DIA
Vice President and Senior Managing Director, Development & Medical Affairs, GlaxoSmithKline Japan -
Lingshi Tan,
PhD •Director DIA
Chairman and Chief Executive Officer
dMed Company Limited -
Cynthia L. Verst,
PharmD •Director DIA
President, R&D Design and Delivery Innovation, IQVIA
-
Joseph Scheeren,
PharmD • Chair, Executive Committee
-
Jeffrey S. Payne,
CPA • Member, Executive Committee -
John A. Roberts,
MBA • Member, Executive Committee -
Rebecca Vermeulen,
RPh • Member, Executive Committee -
Barbara Lopez Kunz,
MS • Member, Executive Committee
-
Michael Romano,
CPA • Chair, Audit Committee -
Andrzej Czarnecki,
MD, PhD, DSc • Member, Audit Committee -
Angelika Joos,
MPharm • Member, Audit Committee -
Joseph Scheeren,
PharmD • Member, Audit Committee -
Cynthia L. Verst,
PharmD • Member, Audit Committee
-
Yoshiaki Uyama,
PhD • Chair, Council of Regulators
Leadership Committee
Japan Pharmaceuticals and Medical Devices Agency Liaison to the DIA Board -
Peter Bachmann,
PhD • Council of Regulators
Leadership Committee
European Medicines Agency Liaison to the DIA Board -
Gerald J. Dal Pan,
MD • Council of Regulators
Leadership Committee
US Food and Drug Administration Liaison to the DIA Board -
Petra Dörr,
PhD • Council of Regulators
Swissmedic Liaison to the DIA Board
-
Barbara Lopez Kunz,
MS • Global Chief Executive -
Bayard G. Gardineer,
MS, CPA • Chief Financial Officer -
Timothy Hess • Global Director of IT
-
Thomas Bols • Senior Vice President & Managing Director
DIA EMEA -
Youngshin Lee,
PhD • Senior Vice President & Managing Director
DIA South Korea and ASEAN -
Sudip S. Parikh,
PhD • Senior Vice President & Managing Director
DIA Americas -
Akio Uemura,
PhD • Senior Vice President & Managing Director
DIA Japan -
Carol Zhu,
RPh, MBA • Senior Vice President & Managing Director
DIA Greater China
A History of Accomplishment
Starting with the controversy over the drug Thalidomide, DIA’s founders - a group of 30 pharmaceutical professionals, medical writers, and academics - came together to create a platform for necessary global communication and collaboration to solve a healthcare threat to unborn children worldwide.
Today, professionals from 80 countries continue to engage with DIA through our unparalleled membership network, educational offerings, and professional development opportunities.